Evidence map›Paper›PMID 29427697›Full record

Trial reportDiabetes research and clinical practice2018

Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes.

E M Venditti, K Tan, N Chang, L Laffel, G McGinley, N Miranda, J B Tryggestad, N Walders-Abramson, P Yasuda, L Delahanty and 1 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes research and clinical practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00081328. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00081328 phase3completed

Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial

Ran2004Enrolled699Registered outcomes11Posted comparisons0ConditionsDiabetes Mellitus, Type IIArmsLifestyle Program, Metformin, Rosiglitazone
PMID 22540912PMID 27803118PMID 24450390PMID 29246363PMID 31167889PMID 29532078PMID 27352955PMID 22332798PMID 31685489PMID 23704674PMID 26537182PMID 29398050other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Worsening glycemic control in youth with type 2 diabetes during COVID-19.Frontiers in clinical diabetes and healthcare · 2022
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

E M VendittiWestern Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
K TanGeorge Washington University Biostatistics Center, Rockville, MD, United States. Electronic address: elghorml@bsc.gwu.edu.
N ChangChildren's Hospital Los Angeles, Los Angeles, CA, United States.
L LaffelJoslin Diabetes Center, Boston, MA, United States.
G McGinleyChildren's Hospital of Philadelphia, Philadelphia, PA, United States.
N MirandaBaylor College of Medicine, Houston, TX, United States.
J B TryggestadUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
N Walders-AbramsonDepartment of Pediatrics, University of Colorado Denver and Children's Hospital Colorado, Aurora, CO, United States.
P YasudaChildren's Hospital Los Angeles and Keck School of Medicine of the University of Southern California, Los Angeles, CA, United States.
L DelahantyMassachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, MA, United States.
TODAY Study Group

Funding

Statistics Center for Pediatric Type 2 Diabetes TherapyU01DK061230 · GEORGE WASHINGTON UNIVERSITY · 2001 to 2005
$69.5M
ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1985 to 2005
$43.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · MASSACHUSETTS GENERAL HOSPITAL · 1985 to 2005
$26.1M
ZIPRASIDONE IN TOURETTES SYNDROME, OBSESSIVE COMPULSIVE &PERVASIVE DEV. DISORDERM01RR000125 · YALE UNIVERSITY · 1985 to 2005
$20.7M
XANAX PET SCAN/IV LACTATE PANIC STUDYM01RR000036 · WASHINGTON UNIVERSITY · 1985 to 2005
$20.4M
ZORVIRAX ORAL SUSPENSION FOR SEVERE CHILDHOOD HERPES VIRUS INFECTIONSM01RR000069 · UNIVERSITY OF COLORADO DENVER · 1985 to 2005
$15.4M
PILOT STUDY--SECRETORY TARGETING IN PANCREATIC B CELLSP30DK036836 · JOSLIN DIABETES CENTER · 1986 to 2025
$12.1M
Washington University Institute of Clinical and Translational SciencesUL1TR002345 · WASHINGTON UNIVERSITY · 2025 to 2025
$9.3M
Trt. of Primary Hyperaldosteronism w/ACE Inhibitors &Angiotension Rec. BlockersM01RR014467 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2001 to 2005
$7.3M
WATER PRECAUTIONS AND TYMPANOSTOMY TUBESM01RR000084 · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · 1985 to 2005
$5.2M
Management of Pediatric Type 2 Diabetes MellitusU01DK061239 · CHILDRENS HOSPITAL OF PHILADELPHIA · 2001 to 2005
$4.6M
Multi-Center Study of the Treatment of T2DM in YouthU01DK061212 · YALE UNIVERSITY · 2001 to 2005
$3.9M
NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR002345NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000043NCRR NIH HHS M01 RR000069NCRR NIH HHS M01 RR000084NCRR NIH HHS M01 RR000125NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR014467NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR024139NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1 RR024989NCRR NIH HHS UL1 RR024992NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1 RR025780NIDDK NIH HHS P30 DK036836NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254
6 · The paper itself

Abstract

aimsExamine barriers for taking glucose-lowering oral medications, associated baseline characteristics, strategies used, and the adherence impact in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study.

methodsWe studied youth prescribed oral diabetes medications over two years (N = 611, 583, and 525 at 6, 12, and 24 months). Clinicians documented barriers (e.g. forgetting, routines, other concerns) in the subsample that reported missed doses (N = 423 [69.2%], 422 [72.4%], and 414 [78.9%] at 6, 12, and 24 months, respectively). Adherence strategies were also assessed (e.g. family, schedule, reminder device) using standard questions. Logistic regression was used to analyze associations with medication adherence.

resultsThose missing doses were not different from the total sample (61.5% female, 13.9 ± 2.0 years, >80% racial/ethnic minorities). No baseline demographic or clinical predictors of barriers to medication adherence were identified. Among those for whom barriers were assessed, "forgetting" with no reason named (39.3%) and disruptions to mealtime, sleep, and schedule (21.9%) accounted for the largest proportion of responses. Family support was the primary adherence strategy identified by most youth (≥50%), followed by pairing the medication regimen with daily routines (>40%); the latter strategy was associated with significantly higher adherence rates (p = 0.009).

conclusionsFamily supported medication adherence was common in this mid-adolescent cohort, but self-management strategies were also in evidence. Findings are similar to those reported among youth with other serious chronic diseases. Prospective studies of multi-component family support and self-management interventions for improving medication adherence are warranted.

trial registrationClinicalTrials.gov NCT00081328.

Indexed as

Communication BarriersDrug MonitoringReminder SystemsAdministration, OralAdolescentChildChronic DiseaseDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHumansHypoglycemic AgentsMaleMedication AdherenceHypoglycemic Agents

Identifiers

PMID29427697
PMCPMC5955779

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.